HIV VPR-specific T-cell receptors

Patent metadata

Field	Value
Publication number	US-10844107-B2
Application number	US-201715659612-A
Country	US
Kind code	B2
Filing date	Jul 25, 2017
Priority date	Mar 25, 2009
Publication date	Nov 24, 2020
Grant date	Nov 24, 2020

Abstract

The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).

First claim

What is claimed is:

1. A method of killing a cell infected with human immunodeficiency virus type 1 (HIV-1), the method comprising: contacting the cell with an isolated T cell receptor (TCR) wherein the isolated TCR has an amino acid sequence according to SEQ ID No. 3, and wherein the HIV-1 expresses an AL9 Vpr peptide.

2. A method for inhibiting replication of human immunodeficiency virus type 1 (HIV-1), the method comprising: administering from 10 μg/kg to 150 λg/kg of an isolated T cell receptor (TCR) wherein the isolated TCR has an amino acid sequence according to SEQ ID No. 3, and wherein the HIV-1 expresses an AL9 Vpr peptide.

3. The method of claim 1 wherein the TCR is a single-chain TCR.

4. The method of claim 1 wherein the TCR is a heterodimeric TCR.

5. The method of claim 2 wherein the TCR is a single-chain TCR.

6. The method of claim 2 wherein the TCR is a heterodimeric TCR.

Assignees

• Altor Bioscience Llc

Inventors

• Fernandez Marilyn
• Liu Bai
• Marcus Warren
• Wong Hing C

Classifications

• C07K14/705 Primary

  Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

• C07K14/70503 Primary

  Immunoglobulin superfamily · CPC title

• G01N33/56988

  HIV or HTLV · CPC title

• A61P31/18

  for HIV · CPC title

• C07K14/7051

  T-cell receptor (TcR)-CD3 complex · CPC title